TriVascular Technologies — Merger or Acquisition (October 2015)
13 slides from TriVascular Technologies's merger presentation, Oct 26, 2015
Slide 1: Combining innovation leaders to revolutionize aortic treatments
OCTOBER 26, 2015 Combining innovation leaders to revolutionize aortic treatments Endologix Third Quarter 2015 Results and TriVascular Merger
Slide 2: Safe Harbor
Safe Harbor Endologix and TriVascular will remain separate operational entities until the closing of the proposed merger transaction. Until closing, Endologix will not offer TriVascular products and TriVascular will not offer Endologix products. Forward-Looking Statements This presentation includes
Slide 3: Endologix 3Q 2015 Results
Endologix 3Q 2015 Results Combining innovation leaders to revolutionize aortic treatments | 10.26.15
Slide 4: Merger Rationale
Merger Rationale Growth Technology Synergies Expanded global sales force Broad product offering for AAA Multiple new product launches over next 24 months An innovation leader with broad clinical indications Significant clinical evidence 370 issued and pending patents Leverages best-in-class technolo
Slide 5: Strong Revenue Growth With A Combined CAGR of 28%
Strong Revenue Growth With A Combined CAGR of 28% Revenue $millions 180 152 160 32 140 20 120 5 148 132 40 83 67 52 2009 2010 2011 2012 2013 2014 Endologix TriVascular Combining innovation leaders to revolutionize aortic treatments | 10.26.15
Slide 6: Innovative Products With Broad Clinical Indications
Innovative Products With Broad Clinical Indications (post merger) Combined portfolio enables physicians to treat the most patients within IFU EVAR EVAS TriVascular Ovation Endologix AFX Endologix Nellix Low profile Narrow & tortuous iliacs Complex necks Reverse taper Preserve bifurcation Tight dista
Slide 7: Significant Clinical Evidence To Drive Adoption
Significant Clinical Evidence To Drive Adoption* (post merger) 2015 2016 2017 Ovation IDE/CAP/PAS (2010) 320 320 320 Global Registry (2011) 501 501 501 LIFE (2014) 200 250 250 LUCY (2015) 20 225 225 Total 1,041 1,296 1,296 AFX IDEs (2000) 707 707 707 PEVAR (2010) 192 192 192 LEOPARD (2015) 150 800 8
Slide 8: Diversified Product Revenue
Diversified Product Revenue (post merger) Total Revenue: $190 million Q4 2014 – Q3 2015 Revenue by product Revenue by geography Ovation 19% U.S. 70% Nellix 13% AFX International 68% 30%
Slide 9: Expanded Global Sales Force
Expanded Global Sales Force (post merger) World-class team of trained sales representatives and clinical specialists Significant growth and cross-selling opportunities Customers in 44 countries across five continents Both
Slide 10: Deep Pipeline Addressing $3B+ Opportunity
Deep Pipeline Addressing $3B+ Opportunity* (post merger) 2015 2016 2017 2018 2019 2020 U.S. CHEVAS Europe THORACIC CHEVAS Asia Pacific (Japan) (Japan) (Japan) (China) (Brazil, Argentina) Latin America CHEVAS (Argentina) (Brazil) *Post-merger estimates based on anticipated regulatory approval timelin
Slide 11: Transaction Overview
Transaction Overview $211 million of consideration consisting of Endologix stock and cash(1) Transaction $9.10 per share Terms 13.56 million Endologix shares, representing ~16.2% ownership ~$24 million in cash consideration ~$13 million for intrinsic value of outstanding equity awards(2) ~$11 millio
Slide 12: Creating a Leader in Growth and Innovation
Creating a Leader in Growth and Innovation Increased revenue growth Broad AAA product line Expanded global sales force Significant clinical evidence $30M+ synergies in 2017 and EBITDA accretive in 2018
Slide 13: Treat more patients more effectively
Treat more patients more effectively
TriVascular Technologies — Merger or Acquisition (October 2015) on 6ix